KA/EN
Register
Medicines reference
Search
Search
Active substance

Artichoke Dry Extract

Favourites

Choleretic plant extract. Not applicable (not a medicine). Forms: tablet.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Artichoke Dry Extract
Georgian name
არტიშოკის მშრალი ექსტრაქტი
Authorisation status
Complementary feed / supplement
Not a medicine and not required to be authorised as one - it is sold under feed law.
Registered in Georgia
0 of 1 forms
Products
Hepatosil Advanced
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Hepatosil Advanced 30 tablets, Tablet

complementary feed for dogs and cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder
4.6/10
Weak evidence support
vetman assessment

Hepatosil Advanced

30 tablets, complementary feed for dogs and cats
Assessed clinical scopeDog · Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder · By mouth
Care settingVeterinarian-directed home adjunct with disease-specific treatment and objective clinical/biochemical monitoring
vetman score 4.6/10 Weak evidence support
Evidence confidence: Low Georgia: Not a medicine · Verified on 22 Oct 2026

A transparent-category but weakly outcome-supported complementary feed. It may be used as a monitored adjunct, but exact-product evidence, quantitative label transparency and dose/formulation certainty do not support stronger claims.

Regulatory and scientific credibility4.5/10

Exact current identity and complementary-feed category are clear, but the manufacturer omits ingredient quantities and detailed cat instructions; those rely on a retailer reproduction, quality standardisation is incomplete and no exact-product trial exists.

Clinical efficacy3.0/10

Ingredient mechanisms and limited dog studies are plausible, but consensus and reviews find weak clinical-outcome evidence; no Hepatosil trial exists, and recent SAMe+silymarin data showed minimal effect without disease-specific therapy.

Safety and tolerability5.5/10

The ingredients are commonly used adjuncts and serious toxicity is not prominent in indirect sources, but exact-product adverse-event rates, long-term diseased-dog safety, interaction testing and reproductive data are absent.

Clinical practicality6.0/10

Once-daily oral use is manageable, but fasting/food separation, double-coat versus crushing uncertainty, ambiguous dosing above 10 kg and undefined duration add meaningful burden.

Full-course cost-effectiveness-

Current exact Georgian course price and an evidence-based duration were not verified; cost is excluded.

Important safety and use flags

  • This is a complementary feed, not a medicine. Medicine-authorisation status is not applicable; that category does not prove clinical efficacy, pharmaceutical equivalence or regulator-reviewed safety.
  • Adjunct only: diagnose and treat the hepatobiliary disorder. Do not substitute this product for nutrition, toxin-specific care, copper management, antimicrobial/immunosuppressive therapy or biliary intervention.
  • No exact-product clinical-outcome, pharmacokinetic/bioavailability or target-animal safety study was located. Ingredient mechanisms and different formulations cannot be added together as product proof.
  • The manufacturer lists ingredients but not per-tablet quantities or a cat-specific dose. Current quantities and feline instructions come from a retailer reproduction of pack information.
  • At the printed schedule, declared SAMe exposure is about 4.5 mg/kg, materially below commonly referenced stable-salt adjunctive dosing. Do not claim equivalence or increase the blend dose by transferring a single-ingredient regimen.
  • The product is described as double-coated, while the reproduced instructions allow crushing into food. SAMe bioavailability after coat disruption is not established; use one deliberate administration method and monitor response.
  • The feline half-tablet instruction is not supported by a verified score line or equal-dose subdivision. Use a validated small-animal presentation when dose accuracy matters.
  • Review polypharmacy: silymarin may inhibit CYP450 enzymes and P-glycoprotein, but exact-product interaction magnitude is unknown. Avoid assuming that “supplement” means interaction-free.
  • Monitor appetite, GI signs, weight, clinical status and disease-appropriate liver biochemistry/imaging. Stop and reassess if objective benefit is absent or the underlying disease progresses.
  • Safety in pregnancy, lactation, neonates and long-term severe organ disease is not established. Use only after an individual benefit-risk review.
Assessment sources
  1. Hepatosil VetaPro page2026
  2. Hepatosil leaflet copy2026
  3. Hepatosil category audit2026
  4. ACVIM canine hepatitis consensus2019
  5. Canine liver nutraceutical review2013
  6. Canine prednisolone SAMe trial2005
  7. Canine GBM hepatoprotectant trial2025
  8. Canine IV LOLA report2016
  9. Healthy-cat SAMe study2005
  10. Feline acetaminophen SAMe study2003
  11. Veterinary cytoprotectant review2009
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder
4.1/10
Weak evidence support
vetman assessment

Hepatosil Advanced

30 tablets, complementary feed for dogs and cats
Assessed clinical scopeCat · Adjunctive nutritional and hepatoprotective support after diagnosis of a hepatobiliary disorder · By mouth
Care settingVeterinarian-directed home adjunct with disease-specific treatment and objective clinical/biochemical monitoring
vetman score 4.1/10 Weak evidence support
Evidence confidence: Low Georgia: Not a medicine · Verified on 22 Oct 2026

A weakly supported complementary feed with especially indirect feline evidence and an unvalidated half-tablet dose unit. It should not replace diagnosis, disease-specific treatment or a validated cat-sized product.

Regulatory and scientific credibility4.5/10

Exact current identity and complementary-feed category are clear, but the manufacturer omits ingredient quantities and detailed cat instructions; those rely on a retailer reproduction, quality standardisation is incomplete and no exact-product trial exists.

Clinical efficacy2.5/10

Feline evidence consists mainly of small experimental SAMe studies using different enteric-coated products; it does not establish benefit for spontaneous feline liver disease or this five-ingredient tablet.

Safety and tolerability5.0/10

A small healthy-cat study supports tolerability of a different SAMe product, but exact-formulation safety in ill cats, interactions, long-term use and reproductive groups are unestablished.

Clinical practicality4.5/10

Once-daily use is simple, but the unscored half-tablet dose is not accuracy-validated, fasting and coating/crushing uncertainty remain, and a separate MINI presentation is better matched to small animals.

Full-course cost-effectiveness-

Current exact Georgian course price and an evidence-based duration were not verified; cost is excluded.

Important safety and use flags

  • This is a complementary feed, not a medicine. Medicine-authorisation status is not applicable; that category does not prove clinical efficacy, pharmaceutical equivalence or regulator-reviewed safety.
  • Adjunct only: diagnose and treat the hepatobiliary disorder. Do not substitute this product for nutrition, toxin-specific care, copper management, antimicrobial/immunosuppressive therapy or biliary intervention.
  • No exact-product clinical-outcome, pharmacokinetic/bioavailability or target-animal safety study was located. Ingredient mechanisms and different formulations cannot be added together as product proof.
  • The manufacturer lists ingredients but not per-tablet quantities or a cat-specific dose. Current quantities and feline instructions come from a retailer reproduction of pack information.
  • At the printed schedule, declared SAMe exposure is about 4.5 mg/kg, materially below commonly referenced stable-salt adjunctive dosing. Do not claim equivalence or increase the blend dose by transferring a single-ingredient regimen.
  • The product is described as double-coated, while the reproduced instructions allow crushing into food. SAMe bioavailability after coat disruption is not established; use one deliberate administration method and monitor response.
  • The feline half-tablet instruction is not supported by a verified score line or equal-dose subdivision. Use a validated small-animal presentation when dose accuracy matters.
  • Review polypharmacy: silymarin may inhibit CYP450 enzymes and P-glycoprotein, but exact-product interaction magnitude is unknown. Avoid assuming that “supplement” means interaction-free.
  • Monitor appetite, GI signs, weight, clinical status and disease-appropriate liver biochemistry/imaging. Stop and reassess if objective benefit is absent or the underlying disease progresses.
  • Safety in pregnancy, lactation, neonates and long-term severe organ disease is not established. Use only after an individual benefit-risk review.
Assessment sources
  1. Hepatosil VetaPro page2026
  2. Hepatosil leaflet copy2026
  3. Hepatosil category audit2026
  4. ACVIM canine hepatitis consensus2019
  5. Canine liver nutraceutical review2013
  6. Canine prednisolone SAMe trial2005
  7. Canine GBM hepatoprotectant trial2025
  8. Canine IV LOLA report2016
  9. Healthy-cat SAMe study2005
  10. Feline acetaminophen SAMe study2003
  11. Veterinary cytoprotectant review2009
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Silymarin250 mg L-Ornithine-L-Aspartate50 mg S-Adenosylmethionine45 mg Artichoke Dry Extract40 mg Vitamin E20 mg
Formulation Type
Tablet
Administration route
By mouth
Manufacturer
VetaPro / Veterinarstvo · Serbia
Registration
Georgia Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 EU Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 UK Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
 US Not a medicine
Not applicable (not a medicine)
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Adjunctive nutritional/hepatoprotective support only after diagnosis and disease-specific management. The manufacturer states one tablet up to 10 kg daily; a retailer-reproduced leaflet states dog one tablet/10 kg and cat half tablet/5 kg daily on an empty stomach. Do not extend the ambiguous schedule above 10 kg or assume an unscored half is equal-dose. A separate MINI presentation exists for small animals.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗